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In this study, we have used genome-wide expression profiling to categorise synovial sarcomas, leiomyosarcomas and malignant
fibrous histiocytomas (MFHs). Following hierarchical clustering analysis of the expression data, the best match between tumour
clusters and conventional diagnosis was observed for synovial sarcomas. Eight of nine synovial sarcomas examined formed a cluster
that was characterised by higher expression of a set of 48 genes. In contrast, sarcomas conventionally classified as leiomyosarcomas
and MFHs did not match the clusters defined by hierarchical clustering analysis. One major cluster contained a mixture of both
leiomyosarcomas and MFHs and was defined by the lower expression of a set of 202 genes. A cluster containing a subgroup of MFHs
was also detected. These results may have implications for the classification of soft tissue sarcomas, and are consistent with the view
that sarcomas conventionally defined as MFHs do not represent a separate diagnostic category.
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Adult soft tissue sarcomas are malignant tumours that occur in
supporting connective tissues throughout the body, other than the
bone or cartilage. They account for around 1% of all cancers and
2% of cancer deaths with metastasis leading to death in about half
of the cases (Dirix and van Oosterom, 1999; Singer et al, 2000;
Weiss and Goldblum, 2001). These tumours are heterogeneous and
a major complication in the management of this disease is that a
definitive classification scheme has been slow to emerge. Synovial
sarcomas are relatively well defined with two clear subcategories
designated monophasic and biphasic, distinguishable following
immunohistochemical examination (Fisher, 1998). The majority of
cases of synovial sarcoma contain a t(X;18)(p11.2;q11.2) transloca-
tion that results in the fusion of the chromosome 18 gene SYT to
three closely related genes SSX1, SSX2 and SSX4 on the X
chromosome (Clark et al, 1994; Crew et al, 1995; Skytting et al,
1999). However, this tumour is of uncertain histogenesis and
despite its name, it does not appear to originate from the
synovium. Leiomyosarcomas are malignant tumours with smooth
muscle differentiation that are defined as a single group based on
morphology and immunohistochemical examination. However,
they exhibit a wide range of clinical behaviour that appears to be
partly related to their site of occurrence, with tumours of the
retroperitonium having poorer prognosis than tumours of the
uterus and extremities (Weiss and Goldblum, 2001). Malignant
fibrous histiocytoma (MFH) until recently was a major diagnostic
category for sarcomas. However, the perceived absence of defining
clinical or histopathological criteria has led to the proposal that
MFH is not a single entity but rather a heterogeneous collection of
poorly differentiated sarcoma types, the majority of which might
be suitably recategorised into other tumour groups, including
leiomyosarcomas, if suitable markers were in hand (Fletcher,
1992).
Since the overall behaviour of a cancer must be determined by
the expression of the genes within it, it should be possible to use
cDNA microarray technology to classify tumours and identify sets
of genes whose expression define individual tumour groups. This
approach has, for example, already been used by Alizadeh et al
(2000) to identify two new subgroups of diffuse large B-cell
lymphoma that had distinct clinical behaviour, and by Golub et al
(1999) to distinguish acute myeloid leukaemia (AML) and acute
lymphoblastic leukaemia (ALL). Recently, Nielsen et al (2002) have
used data obtained using microarrays to molecularly characterise
soft tissue tumours. These results showed that synovial sarcomas,
gastrointestinal stromal tumours (GISTs), neural tumours and a
subset of leiomyosarcomas showed distinct gene expression
patterns. In the current study, we have used cDNA microarrays
to investigate the gene expression profiles for synovial sarcomas,
MFHs and leiomyosarcomas. Our result also show that synovial
sarcomas clustered together exhibiting a characteristic gene
expression profile, but the set of genes whose increased expression
define this group is quite distinct from that described by Nielsen
et al (2002). In addition, we have identified a second major cluster
of tumours that contains both MFHs and leiomyosarcoma and we
provide evidence for the existence of a subset within the MFH
tumour category.
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Tumour and control RNA preparation
Sarcoma tissues were collected from patients undergoing surgery.
Diagnoses were carried out by pathologists using conventional
criteria, immunohistochemistry and electron microscopy. The
tumour samples were snap-frozen in liquid nitrogen and stored at
 801C until RNA extraction. As a common reference sample in
hybridisations, total RNAs from a combination of six cell lines
including three sarcoma cell lines (HTB-175, HTB-115, CCL-121,
CCL-224, T91-95 and HB4a) were used. HTB-175 (small cell lung
cancer), HTB-115 (leiomyosarcoma), CCL-121 (fibrosarcoma) and
CCL-224 (colorectal adenocarcinoma) were obtained from the
American Type Culture Collection. T91-95 (alveolar rhabdomyo-
sarcoma) was obtained from Dr T Gordon (Institute of Cancer
Research, Sutton, UK). HB4a (immortalised human mammary
luminal epithelial cell line) was obtained from Dr MJ O’Hare. Cells
were grown according to the suppliers’ instruction. Total RNA was
extracted from the tumours and cell lines by the TRIZOL
s method
(GibcoBRL, Invitrogen, Paisley, UK).
cDNA microarray slide preparation and RNA labelling
Microarray slides were gridded with the ‘ICR-geneset’ that
consisted of 5603 I.M.A.G.E cDNA clones (including 169 duplicates)
acquired from the UK Human Genome Mapping Project Resource
Centre and Research Genetics (http://www.resgen.com). Informa-
tion on the geneset can be found at http://www.icr.ac.uk/array/
array.html. The preparation of the microarray slides including
gridding and blocking were as described in Clark et al (2002).
Total RNA was labelled by reverse transcription using Super-
script II (Invitrogen, Paisley, UK) using Cy5- or Cy3-labelled
dCTP. Cy5 was used for labelling tumour RNA samples, while Cy3
was used for labelling control cell line pool RNA. Total cellular
RNA (4mg) was reverse transcribed overnight at 371C with 400U
Superscript II (Invitrogen) with 500mM dGTP, dATP and dTTP,
200mM dCTP, 100mM DTT, 100mM Cy5- or Cy3-labelled dCTP
(Amersham, Bucks, UK) and 30mM random primer (50-
IIINNNNNN-30, where I is inosine) (100 excess) in a 20ml
reaction of 1 first-strand buffer (Invitrogen). Labelling reaction
was stopped by the addition of EDTA (pH 8.0) to 90mM. Cot-1
DNA (12.5mg) (Invitrogen) was added. The sample was heated at
701C for 10min in 40mM NaOH. 0.5 SSPE (Sigma, Dorset, UK)
(400ml) was added and the sample was filtered through a 0.1mM
ultrafree-MC filter column (Millipore, Billerica, MA, USA). Sample
volume was then reduced to 30ml using a Microcon YM-30
filtration unit (Millipore). A 400ml volume of 0.5  SSPE (Sigma,
Dorset, UK) was added and this process was repeated twice with a
final reduction in volume to 15ml.
Microarray hybridisation
Prehybridisation of the microarray slide was performed by adding
500ml of prehybridisation mix (6 SSPE pH 7.4, 12.5mM EDTA
pH 8.0, 0.1% (vv
 1) Tween 20) on the slide and incubating at 651C
overnight in a sealed humid box. The microarray slide was then
washed in 4 SSPE, 10mM EDTA for 1min; 2 SSPE, 10mM
EDTA for 1min; and 0.1 SSPE for 1min and drained on a rack.
The microarray slide was then submerged in 70% (vv
 1) deionised
formamide, 2 SSC pH 7.0 at 651C for 1min (denaturation). Slides
were then rinsed twice with 70% ethanol, then with 80 and 100%
(vv
 1) ethanol, blown dry with canned air (RS Components,
Northants, UK) and prewarmed to 371C in a hybridisation
chamber (BDH Precision Engineers, Cambridge, UK) for 30–
60min. The labelled samples (from 4mg each of total RNA from
tumour and control pool) were made up to 50ml in hybridisation
mix (6 SSPE pH 7.4, 12.5mM EDTA pH 8, 0.1% (vv
 1) Tween
20). This mixture was heated to 991C for 2min and then at 651C for
3h. The mixture was then filtered through a 0.1mM ultrafree-MC
filter column (Millipore, Billerica, MA, USA). The filtrate was
heated to 991C for 2min, then at 651C for 10min, and 371C for
10min, pipetted onto a microarray slide and covered with a
Hybrislip (22mm 60mm, Sigma, Dorset, UK). 6  SSPE (300ml)
was pipetted underneath the slide, then the hybridisation chamber
was sealed and incubated at 651C overnight. The slide was then
soaked in 4 SSPE, 10mM EDTA for 1 min at 321C until the
coverslip fell off; and then washed with 4 SSPE, 10mM EDTA for
1min at 321C; 2 SSPE, 10mM EDTA for 1min at room
temperature and 0.1 SSPE for 1 min at room temperature. The
slide was then dried with canned air.
Hybridised microarray slides were scanned in a GenePix 4000A
scanner (Axon Instruments, Foster City, CA, USA). Slides were
scanned at photomultiplier tube (PMT) voltage levels that provided
a Cy5:Cy3 hybridisation ratio across the slide of roughly 1. Ratios
of fluorescent intensities (Cy5:Cy3) for individual cDNA were then
determined after subtraction of background using the GenePix Pro
3.0 software (Axon Instruments, Foster City, CA, USA).
Analysis of microarray data
The scanned image was analysed with the GenePix Pro 3.0 software
(Axon Instruments, Foster City, CA, USA). Fluorescent signals for
both channels of the spots were determined. A local background in
each channel was also determined for each spot, which is the
median fluorescence of pixels in a halo surrounding the same array
spot. Spots or areas of array with defects were flagged bad and were
excluded from subsequent analysis. To enhance the reliability of the
expression data, another round of quality filtering was performed.
Spots with fluorescent spot intensity in each channel that were more
than 1.4 times the local background (medians) of that channel were
considered well measured (Alizadeh et al, 2000), and the data were
further filtered to include only these spots. The median background
intensity was subtracted from the median spot intensity to generate
the background-corrected signal intensity for use in further analysis.
Further analyses including cluster analysis were performed
using the GeneSpring software (Silicon Genetics, Redwood City,
CA, USA). Fluorescent intensity ratios of Cy5:Cy3 for individual
spots of the filtered data were determined by dividing the
background-corrected intensity for the Cy5 by that of the Cy3
channel. These ratios were then normalised by making the median
of all measurements in each sample to be 1. The resulting ratios
were further normalised so that the median of all measurements
taken for a particular gene is 1. In order to better explore the
differences between the samples, a subset of genes showing
normalised expression ratios of above 2 in at least three of the
samples or below 0.5 in at least three of the samples were selected.
Hierarchical clustering was then applied to the log-transformed
data for these genes, using average-linkage clustering with
Pearson’s correlation as the similarity metric. To ensure that
potentially important genes were not excluded, the selection
criteria used was slightly less stringent than those adopted by
Nielsen et al (2002): their clustering studies were carried out on a
subset of genes with an absolute value of fluorescence ratio at least
three times greater than the geometric mean ratio of specimens
looked at, in at least two arrays.
RESULTS
Hierarchical clustering of soft tissue sarcoma expression
profiles
cDNA microarrays containing 5603 I.M.A.G.E. cDNA clones (Clark
et al, 2002) were used to obtain expression profiles for 27 soft
tissue sarcomas including nine synovial sarcomas, nine leiomyo-
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the high reliability of these microarray procedures for identifying
overexpressed genes (Clark et al, 2002). In each experiment, Cy5-
labelled sarcoma cDNA was cohybridised with Cy3-labelled
reference cDNA from pooled human cell lines that served as an
internal standard for the comparison of different experiments.
Following filtering and normalisation, average-linkage hierarchical
clustering analysis was performed on the data set. As we were
specifically interested in the expression differences that may exist
between the different sarcomas, a subset of 833 genes that showed
the most variation in expression among the tumours was used in
the cluster analysis. The resulting dendrogram is shown in Figure 1.
The tumours separated into four clusters. Interestingly, the
clustering of the synovial sarcomas corresponded best to
histological diagnosis. Eight of nine synovial sarcomas clustered
together in a distinct group. A second cluster was composed of a
mixture of five leiomyosarcomas and five MFH tumours. The third
cluster contained a small subset of MFHs, while the fourth group
contained mostly leiomyosarcomas (four) together with an MFH
and the outlying synovial sarcoma.
Gene clustering analysis
Gene clustering groups together genes whose expression patterns
vary in a similar way among the sarcomas examined (Figure 1,
vertical axis). In particular, these analyses identified a synovial
sarcoma cluster of 48 sequences representing 44 different genes
that appeared to have increased expression in synovial sarcoma
compared to leiomyosarcomas and MFHs (Table 1). Each of the 48
sequences in this cluster was resequenced to confirm its identity.
Application of the Wilcoxon – Mann – Whitney test utilising the
Benjamini and Hochberg false discovery rate to correct for
multiple testing (corrected P¼0.01) confirmed that 36 of these
showed statistically significantly different levels of expression in
synovial sarcomas compared to sarcomas in other groups. The
single synovial sarcoma that had a very different expression profile
from other cases of synovial sarcoma was excluded from this
analysis.
The observation that SSX4 is included within the synovial
sarcoma gene set flagged in these analyses demonstrates proof of
principle. Fusion of SYT to SSX1, SSX2 and SSX4 causes
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Figure 1 (A) Two-dimensional cluster analysis of soft tissue sarcomas (horizontal) and 833 genes (vertical). Each column corresponds to a tumour, and
each row corresponds to a gene. Red indicates overexpression relative to the median expression of all the samples, while green indicates underexpression.
Grey indicates missing or excluded data. The dendrogram at the top (tumour clustering) shows the degree of similarity of expression pattern between the
tumours, and the dendrogram on the side (gene clustering) shows the degree of similarity of expression pattern between the genes across the tumour
samples. The shorter the branches, the more similar are the two joined tumours or genes (B) Magnified tumour dendrogram showing the type of tumour.
Abbreviations: MFH, malignant fibrous histiocytoma; Leio, leiomyosarcoma; Synom, monophasic synovial sarcoma; Synob, biphasic synovial sarcoma.
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that is characteristic of this tumour group (Crew et al, 1995;
Skytting et al, 1999). Although SSX1 and SSX2 were not present on
the microarray, they contain significant regions that exactly match
SSX4 sequences and their transcripts would be likely to crossreact
with SSX4 in these microarray studies. The genes present in the
synovial sarcoma represent many functional groups. For example,
they included genes implicated in embryonic development (FGF9),
transcriptional regulation (SSX4, NCOA3), cell signalling (EFNB1)
and cellular adhesion (CDH1, ICAM1). Interestingly, a gene
encoding receptor for the drug cyclosporin A (PPIF) was
overexpressed in synovial sarcoma.
The MFH subgroup appeared to be characterised by the
increased expression of a set of 21 genes (Table 2). This subgroup
is potentially very interesting despite its small size (three tumours),
particularly when considered together with the existence of the
mixed leiomyosarcoma/MFH cluster. Further analysis of a larger set
of MFHs may still be required to confirm its existence and to assess
the significance of these genes. The hierarchical cluster that
contained five leiomyosarcomas and five MFHs was characterised
by low expression of a set of 202 genes (Figure 1). These genes are
listed at http://www.icr.ac.uk/array/array.html (Table A).
DISCUSSION
Genome-wide analysis of gene expression using microarray
technology is proving an important aid in the molecular diagnosis
and classification of human malignancies including leukaemias
and lymphomas (Golub et al, 1999; Alizadeh et al, 2000),
breast cancer (Perou et al, 2000; Sorlie et al, 2001) and melanoma
Table 1 Synovial sarcoma gene cluster
Clone ID UG cluster
a Symbol Gene product
245330 Hs.349109 IGF2 Insulin-like growth factor 2
245330 Hs.349109 IGF2 Insulin-like growth factor 2
754406 Hs.172631 ITGAM
b Integrin, a M
754406 Hs.172631 ITGAM
b Integrin, a M
2242404 Hs.105445 GFRA1
b GDNF family receptor a 1
383188 Hs.80539 RCV1 Recoverin
48799 Hs.78854 ATP1B2
b ATPase, Na
+/K
+ transporting, b 2 polypeptide
197520 Hs.225977 NCOA3
b Nuclear receptor coactivator 3
742082 Hs.1872 PCK1
b Phosphoenolpyruvate carboxykinase 1
950680 Hs.108327 DDB1 Damage-specific DNA binding protein 1
594633 Hs.5338 CA12
b Carbonic anhydrase XII
145112 Hs.168383 ICAM1
b Intercellular adhesion molecule 1 (CD54)
725473 Hs.16349 KIAA0431
b KIAA0431
85259
b Genomic matching AL137072 at 9q31.1
232933 Hs.10755 DPYS
b Dihydropyrimidinase
297061 Hs.10755 DPYS
b Dihydropyrimidinase
753923 Hs.1334 MYB
b MYB transcription factor
80910 Hs.183556 SLC1A5
b Solute carrier family member 5
427750 Hs.1985 SPTA1
b Spectrin, a, erythrocytic 1
384078 Hs.106876 ATP6V0D1
b ATPase, H+ transporting V0 subunit d isoform 1
758343 Hs.173125 PPIF
b Peptidylprolyl isomerase F
46196 Hs.19261 DYT1
b Dystonia 1
884283 Hs.283742
b Retrotransposon
42331 Hs.91916 clone 23892
b Hypothetical protein
267865
b Genomic matching AC104070 at 4q35.2
795325 Genomic matching AL049796 at 1p22-31.1
211548 Hs.73858 CPN2 Carboxypeptidase N, polypeptide 2
1589786 Hs.111 FGF9
b Fibroblast growth factor 9
210575 Hs.2288 VSNL1
b Visinin-like 1
277507 Hs.75652 GSTM5
b Glutathione S-transferase M5
52430 Hs.23106 TRAP100
b Thyroid hormone receptor-associated protein (100kDa)
756968 Hs.144700 EFNB1
b Ephrin-B1
502333 Hs.49765 VLCS-H1
b Very long chain acyl-CoA synthetase homolog1
135085 Hs.154782 AP3S2 Adaptor-related protein complex 3, s 2 subunit
270626 Hs.106415 PPARD
b Peroxisome proliferative activated receptor, d
251019 Hs.194657 CDH1
b Cadherin 1 , E-cadherin
291290 Hs.278632 SSX4
b Synovial sarcoma, X breakpoint 4
727251 Hs.1244 CD9 CD9 antigen
49959 Hs.179747 EVI5 Ectopic viral integration site 5
809598 Hs.151051 MAPK10 Mitogen-activated protein kinase 10
23173 Hs.151051 MAPK10 Mitogen-activated protein kinase 10
221846 Hs.211773 CHES1
b Checkpoint suppressor 1
177737 Hs.29117 PURA
b Purine-rich element-binding protein A
773554 Hs.289043 SPIN
b Spindlin
813742 Hs.82848 SELL Selectin L
797048 Hs.68879 BMP4
b Bone morphogenetic protein 4
813520 Hs.372513 GYPB
b Glycophorin B
233078 Hs.11711 KIAA0329
b KIAA0329
aDNA sequencing was used to confirm the identity of all genes in this table.
bGenes with levels of expression statistically significant
different (corrected P=0.01) in synovial sarcomas compared to sarcomas in other groups by Wilcoxon – Mann – Whitney test utilising
Benjamini and Hochberg false discovery rate to correct for multiple testing.
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microarray technique to obtain expression profiles for three
diagnostic categories of adult soft tissue sarcomas: synovial
sarcomas, leiomyosarcomas and MFHs. Our results show that
most (eight out of nine) synovial sarcomas clustered as a single
group based on their gene expression portrait and that this cluster
was characterised by the raised expression of a set of 48 genes.
Nielsen et al (2002) obtained expression profiles of 41 sarcomas
including eight synovial sarcomas using either 22 or 42k gene
microarrays. In common with our analyses this group found that
synovial sarcomas exhibited a distinct expression profile and
identified a set of genes (104 genes, representing 89 different
genes) whose overexpression appeared to be characteristic of
synovial sarcomas. Remarkably, there was very little overlap
between the genes in this set and those in our synovial sarcoma
gene cluster: indeed the only gene in common was SSX4.I ti s
noteworthy that only 20 of the 44 distinct genes listed in Table 1
were included in the genes used by Nielsen et al (2002) for their
clustering analyses of 41 sarcomas and that only 11 of the 89
distinct genes in the synovial sarcoma cluster of Nielsen et al
(2002) were present in the set of 833 genes selected for our
clustering studies. The lack of correlation may also partly reflect
the need to examine much larger series of individual tumours in
microarray studies before coming to a firm conclusion on the
identity of the genes whose over or underexpression define a
tumour group. This is illustrated by the gene ATP1B2 (Table 1)
that had consistently increased expression in our eight clustered
synovial sarcomas, but was probably not selected by Nielsen et al
(2002) because elevated expression was observed in a lower
proportion of their synovial sarcomas. Conversely BMP7, present
in the synovial sarcoma cluster of Nielsen et al (2002), was
upregulated in only a low proportion of our synovial sarcomas.
Other genes, such as GFRA1, BMP4 and IGF2 that were present in
our cluster, were probably not selected by Nielsen et al (2002)
because they were also upregulated in GIST tumours, a category
not examined in our study. EGFR present in the synovial sarcoma
cluster of Nielsen et al (2002) was not selected in our analysis
because, although upregulated in five of six clustered synovial
sarcoma that had data for this gene, it was also upregulated in one
leiomyosarcoma and four MFHs. It is also noteworthy that in
contrast to the study of Nielsen et al (2002), our analysis did not
distinguish two separate groups of leiomyosarcomas. This might
be related to the fact that only seven of the genes (24 clones
representing 20 different genes) that distinguished their ‘calponin’
subgroups were present in the group of 833 genes used in our
clustering studies.
We have identified a mixed cluster containing both MFH
tumours and leiomyosarcomas that was characterised by low
expression of a set of 202 sequences. When considered together
with our preliminary evidence for a subcategory of MFH tumours,
this observation could be considered to support the proposal of
Fletcher (1992) that MFH does not exist as a single diagnostic
category and that many MFH should be reclassified into groups
with other soft tissue sarcomas, including leiomyosarcomas.
During immunohistochemical diagnosis the detection of mar-
kers such as keratin, epithelial membrane antigen (EMA) and Bcl2
are characteristic of synovial sarcoma (Fisher, 1998). In the current
study, we have confirmed that analysis of microarray expression
profiles can also be used to group most synovial sarcomas in a
single cluster. In addition, groups of genes that could potentially
be used in differential diagnosis or have implications in the
development of sarcoma were identified. We have also provided
evidence on heterogeneity of MFH from a gene expression
perspective that may aid in the development of a definitive
classification scheme for soft tissue sarcomas.
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